Assertio Holdings, Inc., the successor issuer to Assertio Therapeutics, Inc. announced the closing of the merger with Zyla Life Sciences. The combined company will operate under the Assertio name and trade on Nasdaq under the ticker ASRT. With this merger closed, the Company has a board composed of nine directors.

Six directors from the pre-merger Assertio board, including Arthur Higgins, the non-executive chairman, Heather L. Mason, William T. McKee, Peter D. Staple, James L. Tyree and David E. Wheadon. In addition, Todd N. Smith, Timothy P. Walbert, the lead independent director, and Andrea Heslin Smiley joined from the Zyla board. The following persons were appointed the directors of Assertio as of the effective time of the Assertio Reorganization: Daniel A. Peisert and Thomas Allison.

Thomas Allison is appointed as Independent Director. Thomas J. Allison III is a expert in business stabilization/growth. Since May 2018, Mr. Allison has served as a Senior Advisor at Portage Point Partners, a corporate interim management and business advisory firm.

He also serves on the board and Audit Committee chair of Monroe Capital, a position he has held since April 2013. From February to August 2014, Mr. Allison was Chairman of the Board and President of Forge Group, Inc. From 2006 until his retirement in 2012, Mr. Allison served as Executive Vice President and Senior Managing Director of Mesirow Financial Consulting, LLC. At Mesirow, Mr. Allison managed complex turnaround situations and advised on major reorganizations and insolvencies.

He also served as CEO, CFO or CRO for several clients. From 2002 to 2006, Mr. Allison served as National Practice Leader of the restructuring practice of Huron Consulting Group.